Ribonucleic Acid Interference (RNAi) Technology Market Forecast Signals New Revenue Opportunities Through 2030
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Ribonucleic Acid Interference (RNAi) Technology Market Size And Revenue Forecast Through 2030
The market for ribonucleic acid interference (RNAi) technology has experienced substantial expansion over the last few years. Its value is projected to increase from $4.43 billion in 2025 to $5.14 billion in 2026, reflecting a compound annual growth rate (CAGR) of 15.9%. This historical growth has been driven by progress in molecular biology research, early achievements in RNAi therapeutic development, the broadening of academic gene research programs, the accessibility of comprehensive screening libraries, and the flourishing of biotechnology innovation ecosystems.
The market for ribonucleic acid interference (RNAi) technology is projected to experience substantial expansion over the coming years. By 2030, its value is anticipated to reach $9.19 billion, driven by a compound annual growth rate (CAGR) of 15.6%. This forecasted growth is fueled by factors such as the growing commercialization of RNAi-based medications, heightened investment in therapies for rare diseases, advancements in nanoparticle delivery systems, increased pharmaceutical collaborations, and broader regulatory acceptance of gene-silencing treatments. Key trends shaping this period include a greater uptake of gene silencing therapies, expanded use of siRNA-based drug platforms, deeper integration of RNAi into precision medicine, a focus on targeted treatments for genetic disorders, and ongoing improvements in delivery system optimization.
Download A Free Sample Report For Comprehensive Market Insights:
#Ribonucleic Acid Interference (RNAi) Technology Market Growth Factors: Which Forces Are Supporting Market Expansion?
The anticipated expansion of the RNA interference (RNAi) technology market is being significantly driven by the rising demand for targeted therapeutics. These therapies are designed to precisely identify and block molecular abnormalities in diseases such as cancer, thereby enhancing treatment accuracy while reducing damage to healthy cells. This heightened emphasis on targeted treatments largely stems from progress in precision medicine, which customizes therapies based on individual genetic profiles to improve effectiveness. RNAi technology plays a key role in meeting this demand through its capacity for precise gene silencing, particularly for genetic and rare conditions. It fosters the creation of highly specific and potent treatments, encouraging innovation within the realm of personalized medicine. For example, data from December 2024 provided by the American Society of Gene & Cell Therapy (ASGCT), a U.S.-based nonprofit medical and scientific organization, reveals that the FDA approved six gene therapy products in 2023, exceeding the five approvals granted in 2022. Consequently, the growing appetite for targeted therapeutics is propelling the RNAi technology market forward.
Ribonucleic Acid Interference (RNAi) Technology Market Segmentation And Category Breakdown
The ribonucleic acid interference (rnai) technology market covered in this report is segmented –
1) By Product: Micro Ribonucleic Acid (miRNA), Small Interfering Ribonucleic Acid (siRNA), Other Products
2) By Delivery Method: Viral Vectors, Nanoparticles, Chemical Modifications, Physical Methods
3) By Application: Therapeutics, Drug Discovery, Agriculture, Diagnostics
4) By End-User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Contract Research Organizations (CROs) And Contract Manufacturing Organizations (CMOs)
Subsegments:
1) By Micro Ribonucleic Acid (miRNA): Micro Ribonucleic Acid Mimics, Micro Ribonucleic Acid Inhibitors, Micro Ribonucleic Acid Expression Vectors, Micro Ribonucleic Acid Profiling And Quantification Kits
2) By Small Interfering Ribonucleic Acid (siRNA): Small Interfering Ribonucleic Acid Synthetic Duplexes, Small Interfering Ribonucleic Acid Dicer Substrate Molecules, Small Interfering Ribonucleic Acid Self Delivering Conjugates, Small Interfering Ribonucleic Acid N Acetylgalactosamine Conjugates
3) By Other Products: Short Hairpin Ribonucleic Acid Expression Constructs, Ribonucleic Acid Interference Screening Libraries, Ribonucleic Acid Interference Transfection Reagents, Micro Ribonucleic Acid And Small Interfering Ribonucleic Acid Research Kits
Ribonucleic Acid Interference (RNAi) Technology Market Industry Trends: What Changes Are Reshaping Demand?
Major players within the RNA interference (RNAi) technology sector are actively pursuing platform integration, specifically through strategic funding and support, in order to optimize the development, delivery, and commercialization of RNAi therapeutics. This approach helps maintain a sustainable pipeline of multiple programs targeting various disease areas. Strategic funding and support involves obtaining investment and resources from venture capital firms, industry partners, and other stakeholders to speed up the research, development, and commercialization of RNAi treatments. As an example, in October 2024, City Therapeutics Inc., a US-based biopharmaceutical company, secured $135 million in Series A financing led by ARCH Venture Partners, with additional contributions from other prominent life sciences investors, to advance the future of RNAi-based medicine. This funding will be utilized to progress RNAi medicine by capitalizing on its proprietary lipid nanoparticle (LNP) delivery system, specifically engineered to target tissues other than the liver with high accuracy. This platform aims to address a significant historical challenge in this field, thereby facilitating the creation of therapies for a broader spectrum of genetic conditions.
Ribonucleic Acid Interference (RNAi) Technology Market Competitive Analysis Of Major Industry Participants
Major companies operating in the ribonucleic acid interference (rnai) technology market are F. Hoffmann-La Roche AG, Merck KGaA, Novartis AG, Thermo Fisher Scientific Inc., Danaher Corporation, Revvity Inc., QIAGEN N.V., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., GenScript Biotech Corporation, Promega Corporation, Arrowhead Pharmaceuticals Inc., Silence Therapeutics plc, Creative Biolabs Inc., Bioneer Corporation, Genevant Sciences Ltd., Gradalis Inc., Altogen Labs LLC, Sirnaomics Inc., Altogen Biosystems Inc.
Access The Complete Ribonucleic Acid Interference (RNAi) Technology Market Report:
Ribonucleic Acid Interference (RNAi) Technology Market Largest Region: Which Geography Holds The Highest Market Share?
North America was the largest region in the ribonucleic acid interference (RNAi) technology market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ribonucleic acid interference (rnai) technology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
